VANCOUVER, British Columbia, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Trailbreaker Resources Ltd. (TBK.V) ("Trailbreaker" or "the Company") announces that subject to all regulatory approvals, the Company has granted 800,000 incentive stock options to directors, officers, and certain consultants of the Company. All Options issued pursuant to this grant shall vest immediately, have a term of 5 years and are exercisable at $0.43.
ON BEHALF OF THE BOARD
Daithi Mac Gearailt President and Chief Executive Officer
For new information about the Company's projects, please visit Trailbreaker's website at TrailbreakerResources.com and sign up to receive news. For further information, follow Trailbreaker's tweets at Twitter.com/TrailbreakerLtd, use the ?Contact' section of our website, or contact us at (604) 681-1820 or at [email protected].
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
TRAILBREAKER RESOURCES LTD. 650 W. Georgia Street, #2110 Vancouver, British Columbia Canada, V6B 4N9
eWTP Arabia Capital Technology Fund I ("Techology Fund I"), managed by eWTP Arabia Capital ("eWTPA"), one of the leading private equity firms in the Middle East, was listed in the Preqin League Tables as the the fifth top-performing VC funds in the...
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024).
The campaign focuses on access to IBD care and treatment as the burden of...
The global industrial automation market in life sciences industry size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 11.4% during the forecast period. ...
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...